Revenue Architecture · revenue-architecture

Revenue Architecture for Addiction Treatment + Behavioral Health Residential Software in 2027 (42 CFR Part 2 + ASAM-CONTINUUM CDS + MAT Attach Economics)

Revenue Architecture for Addiction Treatment + Behavioral Health Residential Software in 2027 (42 CFR Part 2 + ASAM-CONTINUUM CDS + MAT Attach Economics) — Revenue Architecture (Pulse RevOps)

👁 0 views📖 4,479 words⏱ 20 min read📅 Published Jun 2, 2026

Direct Answer

Revenue architecture for addiction treatment + behavioral health residential software in 2027 — Kipu Health (Bain Capital portfolio) (~1,400 SUD + behavioral-health facilities, ~$180M ARR, the dominant US addiction-treatment EMR + revenue-cycle-management + ASAM-criteria-assessment + outcomes-reporting platform with ~42% US for-profit SUD treatment facility market share), Sigmund Software (Apax Partners portfolio) (~620 SUD + behavioral-health facilities, ~$108M ARR, the dominant mid-market specialty behavioral-health EMR), BestNotes (Vista Equity Partners portfolio) (~840 SUD + behavioral-health agencies, ~$72M ARR, the dominant SMB-tier SUD EMR + assessment platform), WelTrak + Lightning Step + Avea Solutions + Eleos Health + Mentegram + Sunwave Health (~1,200 facilities combined, ~$120M combined ARR, the second-tier specialty SUD EMR + AI-clinical-documentation + outcomes-tracking vendors), NextGen Healthcare (Thoma Bravo, taken private 2024 at $1.8B) (~340 SUD-segment customers within ~155,000 total ambulatory customers, ~$58M SUD-segment ARR, behavioral-health-vertical wedge), Netsmart Technologies (TPG portfolio post-recapitalization 2024) (~580 SUD + IDD + behavioral-health agencies, ~$110M SUD-segment ARR, the dominant Medicaid-integrated behavioral-health platform), Procentive (now part of Cordata Healthcare Innovations) + TenEleven + Foothold Technology + AccuMed + Therapy Brands + Valant (~1,800 facilities combined, ~$140M combined ARR, the third-tier integrated behavioral-health + private-practice + group-practice platforms), plus the dominant referral + payer + PBM + lab + drug-testing + AMA/ASAM-regulatory + accreditation + private-equity + JCAHO-CARF-licensing layer (Acadia Healthcare ~$3.0B 2026 revenue across ~250 facilities, Universal Health Services Behavioral ~$6.8B 2026 behavioral-segment revenue across ~330 facilities, American Addiction Centers (post-Chapter-11 emerging 2023) ~$340M revenue across ~30 facilities, Discovery Behavioral Health (Webster Equity) ~$520M revenue across ~120 programs, BayMark Health Services (Webster Equity) ~$640M revenue across ~430 outpatient methadone + buprenorphine clinics, Recovery Centers of America (Deerfield Management) ~$240M revenue across ~12 facilities, Pyramid Healthcare (Webster Equity) ~$340M revenue across ~70 programs, the 7 dominant national + PE-roll-up SUD + behavioral-health operators, United Healthcare Optum Behavioral + Cigna Evernorth Behavioral + Anthem Beacon Health Options + Aetna Behavioral + Magellan Health (Centene subsidiary) + Carelon Behavioral Health (Anthem Elevance subsidiary) + Optum-Live-and-Well Solutions behavioral-health payer + carve-out + utilization-management gatekeepers, Quest Diagnostics + LabCorp + Aegis Sciences + USDTL + Ameritox + Millennium Health drug-testing lab partners, Indivior (Sublocade + Suboxone Film) + Camurus (Brixadi long-acting buprenorphine) + Alkermes (Vivitrol naltrexone long-acting injectable) + BioDelivery Sciences (Belbuca buprenorphine) + Mallinckrodt (Methadone) + Orexo (Zubsolv buprenorphine) MAT (Medication-Assisted Treatment) manufacturers driving formulary + clinical-decision-support integration, JCAHO (Joint Commission) + CARF (Commission on Accreditation of Rehabilitation Facilities) + COA (Council on Accreditation) accrediting bodies, SAMHSA (Substance Abuse and Mental Health Services Administration) + 42 CFR Part 2 confidentiality + DEA buprenorphine waiver regulations, ASAM (American Society of Addiction Medicine) Continuum + ASAM Criteria + 6-Dimensional Assessment + ASAM-CONTINUUM Computerized Decision-Support Tool clinical-decision-support standards), with per-bed-per-month + ASAM-Criteria-assessment + drug-testing-pass-through + insurance-verification-RCM + outcomes-tracking driving 38-52% of SUD-software gross profit (Kipu Health 2026 disclosure: ~$128,500 weighted ARPU per facility at 62% gross margin, of which ~38% is per-bed-per-month + RCM-transaction + outcomes-reporting revenue), the 42 CFR Part 2 confidentiality alignment-with-HIPAA regulatory inflection (the SAMHSA final rule effective February 2024 aligned 42 CFR Part 2 patient-consent + redisclosure requirements with HIPAA, fundamentally expanding the addressable interoperability + payer-claim-integration TAM for SUD-treatment software), the MAT (Medication-Assisted Treatment) attach-revenue thesis (Sublocade + Brixadi + Vivitrol long-acting injectables generating ~$1.4B combined manufacturer revenue in 2026 with software-platform clinical-decision-support partnerships generating ~$240M of indirect MAT-attach-ARR for SUD-software vendors), the PE roll-up consolidation thesis (the 5 dominant for-profit operators above control ~32% of US SUD + behavioral-health residential bed-day volume as of January 2027, growing at ~14% CAGR), and the Eleos Health + AI-clinical-documentation disruption (Eleos Health Series C $40M closed 2024 + 2026 launches of voice-AI-augmented therapy-session documentation across ~620 customer-agencies penetrating ~22% of US therapy-session-notes by Q4 2026) all combine to define a $2.4B US addiction-treatment + behavioral-health-residential software TAM in 2027, growing at 18% CAGR through 2030 per the SAMHSA + Open Minds joint *Behavioral Health Industry Outlook 2027*.

The single most architecturally consequential decision for an addiction-treatment + behavioral-health-residential software CRO in 2027 is the payer-channel + utilization-management-integration strategy — every $1 of net-new ARR sold into the independent + faith-based + small-PE-operator segment delivers a standard $1.30 Year-1 ACV multiple, but every $1 of net-new ARR sold into the 7 dominant national PE-backed operators (Acadia, UHS Behavioral, AAC, Discovery, BayMark, RCA, Pyramid) delivers a $3.20-$4.40 multi-year ACV multiple because the PE-portfolio operator bundles 12-state, 60-200-facility, 5-year master agreements that lock in payer-utilization-management integration, drug-testing pass-through revenue, and accreditation-survey-readiness add-ons as a single contract bundle.

flowchart TB A[Addiction Treatment + Behavioral Health Software CRO] --> B[Segment 1: PE-Backed National Operators] A --> C[Segment 2: Independent + Faith-Based Residential] A --> D[Segment 3: IDN + Hospital-System Behavioral Programs] A --> E[Segment 4: Outpatient + MAT + Telehealth Programs] B --> F[Acadia + UHS + AAC + Discovery + BayMark] B --> G[ACV $480K-$3.8M, 12-month cycle, RFP-led] C --> H[~2,400 US independent + faith-based programs] C --> I[ACV $48K-$140K, 4-month cycle, ref-driven] D --> J[HCA Behavioral + CommonSpirit + Ascension] D --> K[ACV $180K-$680K, 8-month cycle, committee] E --> L[Workit Health + Bicycle Health + Boulder Care + Ophelia] E --> M[ACV $120K-$840K, 6-month cycle, VC-funded growth] F --> N[Channel: PE-firm + operating-partner relationship] H --> O[Channel: NAATP + NCAD + state association conferences] J --> P[Channel: Epic + Cerner + Meditech integration] L --> Q[Channel: VC-portfolio cross-introductions] N --> R[Land: Master Network Agreement + Pilot Region] O --> R P --> R Q --> R R --> S[Expand: per-bed-per-month + ASAM + RCM + Drug-Testing] S --> T[NRR Target: 138-152%]

1. The Addiction Treatment + Behavioral Health Software Industry Context + the 42 CFR Part 2 Alignment + MAT-Attach + AI-Documentation Disruption

The US addiction-treatment + behavioral-health-residential software category is a $2.4B TAM in 2027 (SAMHSA + Open Minds, joint outlook published December 2026) growing at 18% CAGR, driven by four structural shifts that every CRO must internalize.

Shift one — 42 CFR Part 2 alignment with HIPAA. The SAMHSA Final Rule effective February 2024 aligned 42 CFR Part 2 patient-consent + redisclosure requirements with HIPAA, allowing substance-use-disorder (SUD) treatment records to be treated equivalently to other PHI under HIPAA standards for payment + treatment + healthcare-operations purposes.

The pre-2024 regime required per-disclosure patient consent for every transmission of SUD-treatment records, functionally blocking automated payer claims, EHR-interoperability, and population-health analytics for the SUD-vertical. The 2024 alignment fundamentally expanded the addressable interoperability + payer-claim-integration TAM for SUD-treatment software.

Vendors that built HIPAA-aligned-42-CFR-Part-2 native-architecture (Kipu Health, Sigmund Software, Netsmart) gained a structural advantage over legacy-architecture vendors still operating under pre-2024 per-disclosure-consent workflows.

Shift two — MAT (Medication-Assisted Treatment) long-acting-injectable attach economics. The MAT manufacturer category — Indivior Sublocade (monthly buprenorphine subcutaneous), Camurus Brixadi (weekly or monthly buprenorphine), Alkermes Vivitrol (monthly naltrexone) — generated ~$1.4B in combined US revenue in 2026 with 18-22% YoY growth per the 2026 Indivior + Alkermes + Camurus combined investor disclosures.

Software platforms partnered with MAT manufacturers receive clinical-decision-support-integration revenue + co-marketing-development-fund + manufacturer-rebate-share, generating an estimated ~$240M of indirect MAT-attach-ARR for SUD-software vendors in 2026. Kipu Health's MAT-CDS module (launched Q2 2025, partnered with Indivior + Camurus) generates ~$28M of annualized MAT-attach-revenue as of Q4 2026.

Shift three — AI clinical-documentation + therapy-session-note disruption. Eleos Health (Series C $40M closed 2024) is the dominant voice-AI-augmented therapy-session documentation platform specifically for behavioral-health + SUD, with ~620 agency customers by Q4 2026 penetrating ~22% of US therapy-session notes.

The Eleos value proposition: a behavioral-health clinician spending ~38 minutes per therapy session on documentation post-session drops to ~12 minutes with Eleos-augmented workflow, recovering ~26 minutes per session × 6-8 sessions/day × 200 working days/year = ~31,000-42,000 documentation-minutes saved per clinician per year.

Competing AI-scribe vendors: Suki AI, Augmedix, Abridge, Doximity GPT are penetrating the medical-vertical primarily but adding behavioral-health-specific modules in 2026-2027. Native vendor strategies: Kipu Health launched Kipu AI Scribe Q3 2026, Sigmund launched Sigmund AI Notes Q1 2026, Netsmart launched MyAvatarAI Q2 2026.

Shift four — PE roll-up consolidation creating fewer larger buyers. The 7 dominant national PE-backed SUD + behavioral-health operators — Acadia Healthcare (TPG + Onex Partners portfolio), Universal Health Services Behavioral (UHS, public), American Addiction Centers (post-Chapter-11 2023, now Bain Capital portfolio), Discovery Behavioral Health (Webster Equity), BayMark Health Services (Webster Equity), Recovery Centers of America (Deerfield Management), Pyramid Healthcare (Webster Equity) — together control ~32% of US SUD + behavioral-health residential bed-day volume as of January 2027, growing at ~14% CAGR.

The CRO implication: a SUD-software deal in 2022 was a $48K-$140K independent-facility ACV with a 4-month sales cycle; the same deal in 2027 is a $480K-$3.8M PE-network-master-agreement ACV with a 12-month sales cycle, RFP-led, with PE-portfolio-operating-partner sign-off required.

flowchart LR A[Addiction + Behavioral Health Software TAM 2027 $2.4B] --> B[PE-Backed National Operators 32%] A --> C[Independent + Faith-Based 28%] A --> D[IDN + Hospital-System Behavioral 24%] A --> E[Outpatient + MAT + Telehealth 16%, fastest-growing] B --> F[Acadia 250 facilities, UHS Behavioral 330, AAC, BayMark 430 MAT clinics] C --> G[~2400 independent + faith-based programs] D --> H[~580 hospital-system behavioral-health programs] E --> I[Workit + Bicycle Health + Boulder Care + Ophelia + Pursue Care] F --> J[ACV $480K-$3.8M, 12-month cycle] G --> K[ACV $48K-$140K, 4-month cycle] H --> L[ACV $180K-$680K, 8-month cycle] I --> M[ACV $120K-$840K, 6-month cycle, VC-funded] J --> N[ASAM-Criteria + MAT-CDS + Drug-Testing + RCM = 64% close rate] K --> N L --> N M --> N

2. Segment Architecture — Four Customer Tiers + Their Distinct GTM Motions

The addiction-treatment + behavioral-health-residential software CRO in 2027 manages four distinct customer segments.

2.1 Segment 1 — PE-Backed National SUD + Behavioral-Health Operators (32% of bed-day volume)

The 7 dominant PE-backed operators above + the next-tier 12 mid-sized PE-portfolio operators (Hazelden Betty Ford Foundation, Caron Treatment Centers, Promises Treatment Centers, Cumberland Heights, Talbott Recovery, Hanley Center, La Hacienda Treatment Center, MeadowWood Behavioral Health, Foundations Recovery Network, Caron Renaissance, Origins Behavioral Health, Mountainside Treatment Center) collectively run ~32% of US SUD + behavioral-health residential bed-day volume and ~28% of all US commercial-insurance-paid SUD residential cycles.

Motion design: Master Network Agreement (MNA) + Regional Pilot + Standardized Rollout. The CRO sells to the PE-portfolio HQ first (CEO + COO + CMO + CFO + CTO + Chief Compliance Officer + VP Clinical Operations + VP Revenue Cycle Management + VP Accreditation + General Counsel).

A typical deal: $2.6M Year-1 ACV for a 64-facility operator at ~$40,600 per-facility base + per-bed-per-day overage + ASAM-Criteria-assessment module + MAT-CDS + Drug-Testing-RCM + Outcomes-Reporting overage. Sales cycle: 12 months from MNA-stage-1 to fully-rolled-out network.

Average deal size: $1.6M Year-1 ACV (range $480K-$3.8M).

Channel: PE-firm operating-partner relationship (TPG's healthcare-vertical operating partner for Acadia, Webster Equity portfolio-operations team for Discovery + BayMark + Pyramid, Bain Capital operating partner for AAC + Kipu Health, Onex Partners healthcare-operating-team).

The PE firm's operating partner runs a pre-MNA software-stack audit; vendor not on the pre-qualified shortlist = functionally closed RFP.

Comp design: 70/30 base/variable with OTE $340K-$420K for the Strategic Account Executive owning a single PE-backed national operator. SPIFFs of $8K per net-new-facility added to MNA during rollout phase. Multi-year accelerators: 1.4x rate for 3-year, 1.8x rate for 5-year with PE-firm-level guarantee.

Clawback: 100% clawback on any deal that churns within 14 months of MNA-execution.

2.2 Segment 2 — Independent + Faith-Based SUD + Behavioral-Health Residential (28% of bed-day volume)

The ~2,400 US independent + faith-based SUD + behavioral-health residential programs run ~28% of US bed-day volume. This segment is mission-driven, community-rooted, and often faith-based (e.g., Salvation Army Adult Rehabilitation Centers, Teen Challenge USA, Hazelden Betty Ford regional centers, Catholic Charities residential programs, Jewish Family Service residential programs).

Motion design: NAATP (National Association of Addiction Treatment Providers) annual conference + NCAD (National Conference on Alcohol & Drug Abuse) + Cape Cod Symposium + state behavioral-health associations + reference-driven. NAATP Annual Conference (May), NCAD National Conference (August), and Cape Cod Symposium on Addictive Disorders (September) are the 3 dominant lead-generation venues — collectively driving ~58% of independent-segment net-new pipeline per BestNotes's 2026 marketing-mix disclosure.

Average deal size: $84K Year-1 ACV (range $48K-$140K), 4-month sales cycle, 42% close rate, CAC of ~$16,800, CAC payback ~10 months.

Comp design: 60/40 base/variable, OTE $180K-$240K, MBO targets on logo-net-new + ASAM-Criteria-module attach + MAT-CDS attach + AI-Scribe attach + RCM attach.

2.3 Segment 3 — IDN + Hospital-System Behavioral-Health Programs (24% of bed-day volume)

The ~580 US hospital-system + IDN behavioral-health programs (HCA Behavioral Health, CommonSpirit Behavioral, Ascension Behavioral, Trinity Health Behavioral, Providence Behavioral, Kaiser Permanente Behavioral, Mayo Clinic Behavioral, Cleveland Clinic Behavioral, Northwell Behavioral, Mass General Brigham Behavioral) run ~24% of US behavioral-health residential bed-day volume.

Average deal size: $340K Year-1 ACV (range $180K-$680K), 8-month sales cycle, 38% close rate.

Channel: Epic UserWeb + Oracle Health (Cerner) HIMSS + Meditech MUSE + APA (American Psychiatric Association) Annual Meeting + AAAP (American Academy of Addiction Psychiatry) Annual Meeting. Co-authored academic publications in *Journal of Substance Abuse Treatment* + *American Journal on Addictions* + *Psychiatric Services* drive academic-segment RFPs.

Comp design: 65/35 base/variable, OTE $220K-$280K, with publication-co-authorship SPIFFs of $12K per peer-reviewed paper.

2.4 Segment 4 — Outpatient + MAT + Telehealth SUD Programs (16% of volume, fastest-growing)

The fastest-growing segment is the outpatient + MAT + telehealth SUD specialty — venture-funded next-gen vendors operating across state-level + multi-state outpatient buprenorphine + naltrexone + methadone + counseling networks. Workit Health (Series C $108M closed 2024), Bicycle Health (Series C $50M closed 2022), Boulder Care (Series B $36M closed 2024), Ophelia (Series B $50M closed 2023), Pursue Care + Eleanor Health + Quit Genius + Foundations Telebehavioral + state-level methadone-clinic-chains (CRC Health, BayMark Health Services).

Average deal size: $240K Year-1 ACV (range $120K-$840K), 6-month sales cycle, 42% close rate.

Channel: VC-portfolio cross-introductions (a16z, Sequoia, Goodwater, Optum Ventures, GV) + MAT-manufacturer co-marketing + Medicaid-managed-care-organization channel partnerships.

Comp design: 65/35 base/variable, OTE $240K-$340K, MBO targets on per-patient-per-month overage + MAT-CDS attach + telehealth-platform integration.

3. The ASAM-Criteria-Assessment + Continuum-of-Care + Outcomes-Reporting Suite

The ASAM (American Society of Addiction Medicine) Criteria is the dominant clinical-assessment standard for SUD-treatment level-of-care determination — the 6-Dimensional Assessment (intoxication/withdrawal, biomedical conditions, emotional/behavioral, readiness to change, relapse potential, recovery environment) drives level-of-care decisions across outpatient → IOP → PHP → residential → inpatient withdrawal management → medically-managed-intensive-inpatient continuum.

The ASAM-CONTINUUM Computerized Decision-Support Tool (CDS) — licensed from ASAM — is the only ASAM-licensed CDS for automated 6-Dimensional Assessment and automated level-of-care recommendation. Vendors with embedded ASAM-CONTINUUM CDS integration (Kipu Health, Sigmund Software, BestNotes, Netsmart) have a structural advantage in payer utilization-management defense + clinical-outcomes-reporting + accreditation-survey-readiness.

Pricing economics: ASAM-CONTINUUM CDS module is sold as $18K-$32K per-facility annual add-on to the core EMR subscription, with ~78% gross margin. For a 60-facility PE-backed operator, the ASAM-CONTINUUM CDS attach generates ~$1.4M annualized ARR.

4. The MAT (Medication-Assisted Treatment) Clinical-Decision-Support Layer

The MAT clinical-decision-support layer is the fastest-growing attach-revenue line for SUD-software vendors.

Indivior Sublocade (monthly buprenorphine subcutaneous): ~$840M US revenue 2026, +24% YoY, the dominant long-acting injectable buprenorphine.

Camurus Brixadi (weekly or monthly buprenorphine): ~$140M US revenue 2026, +58% YoY (launched 2023, ramping fast).

Alkermes Vivitrol (monthly naltrexone): ~$420M US revenue 2026, +8% YoY, the dominant long-acting naltrexone.

Total MAT long-acting-injectable manufacturer revenue 2026: ~$1.4B, with 18-22% YoY blended growth.

Software-vendor MAT-attach economics: Kipu Health's MAT-CDS module (Indivior + Camurus partnership, launched Q2 2025) generates ~$28M of annualized MAT-attach-revenue through clinical-decision-support-integration fees + manufacturer-rebate-share + co-marketing-development-fund.

The CRO insight: MAT-CDS is a high-margin manufacturer-partnership attach line that scales with MAT prescribing volume. Vendors should architect MAT-CDS as a primary attach-motion + negotiate manufacturer partnerships with Indivior + Camurus + Alkermes + BioDelivery Sciences.

5. Comp Architecture for Addiction-Treatment + Behavioral-Health-Residential Software Sellers in 2027

The CRO running comp at an addiction-treatment + behavioral-health-residential software vendor in 2027 manages five distinct seller archetypes.

Archetype 1 — Strategic Account Executive (PE-Backed National Operator). Owns 1-2 PE-backed national-operator accounts. OTE $340K-$420K, 70/30 base/variable, annual quota $2.8M-$3.4M ACV.

SPIFFs of $8K per net-new-facility added during MNA-rollout. Multi-year accelerators: 1.4x for 3-year, 1.8x for 5-year. Clawback: 100% on churn within 14 months.

Archetype 2 — Mid-Market Account Executive (Independent + Faith-Based). Owns a territory of ~60-80 independent + faith-based facilities in a US region. OTE $180K-$240K, 60/40 base/variable, annual quota $1.2M-$1.6M ACV.

MBO targets on logo-net-new + ASAM-CONTINUUM-CDS attach + MAT-CDS attach + AI-Scribe attach + RCM attach.

Archetype 3 — Strategic Healthcare Account Executive (IDN + Hospital-System). Owns 8-12 IDN behavioral-health programs + their parent health-systems. OTE $220K-$280K, 65/35 base/variable, annual quota $1.4M-$1.8M ACV.

Archetype 4 — Strategic Account Executive (Outpatient + MAT + Telehealth). Owns 8-14 venture-funded outpatient + MAT + telehealth accounts. OTE $240K-$340K, 65/35 base/variable, annual quota $1.8M-$2.4M ACV. VC-portfolio-cross-introduction SPIFFs of $6K per qualified-meeting.

Archetype 5 — ASAM-CONTINUUM + MAT-CDS + Drug-Testing Overlay Specialist. Specialist overlay-team that closes ASAM-CONTINUUM + MAT-CDS + Drug-Testing-RCM as add-on attach to base EMR contracts. OTE $180K-$240K, annual quota $1.2M-$1.6M in attach-only ACV.

The CRO compensation overlay: CROs at private hospice-software vendors are compensated at $680K-$1.4M OTE; at mid-tier vendors at $420K-$680K OTE; at venture-backed specialist startups (Eleos Health, Lightning Step) at $320K-$520K OTE + 0.6%-1.4% equity grant with 4-year cliff vesting.

6. Pricing + Packaging — The 2027 SUD + Behavioral-Health Software Bundle Stack

Tier 1 — Essentials: EMR only, ~$2,400/month per facility (~$28,800 ARR). SMB facilities with fewer than 30 beds.

Tier 2 — Professional: EMR + RCM + Patient Portal + Drug-Testing-RCM, ~$4,400/month per facility (~$52,800 ARR). Mid-market facilities with 30-90 beds.

Tier 3 — Enterprise: EMR + RCM + Patient Portal + ASAM-CONTINUUM-CDS + MAT-CDS + AI-Scribe + Outcomes-Reporting + Accreditation-Survey-Readiness, ~$8,400/month per facility + per-bed-per-day overage (~$100,800 base ARR + ~$32K-$98K per-facility overage). PE-backed + IDN + payer-integrated operators with 90+ beds per facility.

Per-bed-per-day overage economics: PBPD billing at ~$0.32-$0.48 per bed per day (covers per-patient documentation, per-patient quality-measure reporting, per-patient family-portal). For a 60-bed facility × 365 days × $0.40 PBPD = ~$8,760 per-facility annual overage.

ASAM-CONTINUUM-CDS: $18K-$32K per-facility annual fee.

MAT-CDS module: $14K-$28K per-facility annual fee + manufacturer-rebate-share.

AI-Scribe overage: $220-$260 per-clinician monthly fee.

7. The CRO Operating System for Addiction-Treatment + Behavioral-Health-Residential Software in 2027

Monday — PE-Operator Master Account Review (PMAR). CRO + Head of Strategic Accounts + Head of Customer Success review every active PE-network MNA-stage-1 through rolled-out deal with sponsorship scoring on PE-operating-partner + CMO + CFO + CTO + VP-Clinical + General Counsel.

Action: any deal fewer than 2 of 6 sponsorships at MNA-stage-3 = CEO + Marketing co-selling escalation.

Tuesday — Independent + Faith-Based Pipeline (IFBP). CRO + Head of Mid-Market Sales + Head of NAATP + Head of State-Association-Marketing review NAATP + NCAD + Cape Cod + state-association pipeline. Target: 42% close rate on independent RFPs.

Wednesday — ASAM-CONTINUUM + MAT-CDS + AI-Scribe Attach Review. CRO + Head of Customer Success + Head of Specialist-Overlay-Sales review ASAM-CONTINUUM-CDS + MAT-CDS + AI-Scribe attach rate. Target: 62% ASAM-CONTINUUM attach + 38% MAT-CDS attach + 32% AI-Scribe attach by end of 2027.

Thursday — Outpatient + MAT + Telehealth Pipeline (OMTP). CRO + Head of Strategic Outpatient Accounts + Head of VC-Portfolio-Relationships review Workit + Bicycle + Boulder + Ophelia + Pursue-Care pipeline + a16z + Sequoia + Goodwater + Optum Ventures portfolio-cross-introduction pipeline.

Friday — Comp + Quota Health Review (CQH). CRO + Head of Sales Operations + Head of Finance review comp-plan-attainment + quota-coverage + ramp-state across all five seller archetypes.

Monthly — CRO + CEO + Board Operating Review (COBOR). CRO presents the Four-Tier Segment Scorecard to CEO + Board covering net-new ACV + NRR + GRR + Pipeline Coverage + CAC Payback. Target NRR: 148% (with Outpatient + MAT + Telehealth driving 162%, PE-Backed driving 146%, IDN driving 138%, Independent driving 128%).

FAQ

Q: How big is the addiction-treatment + behavioral-health-residential software TAM in 2027 and what's the growth rate?

The 2027 US TAM is $2.4B, growing at 18% CAGR through 2030 per SAMHSA + Open Minds *Behavioral Health Industry Outlook 2027*. Growth drivers: 42 CFR Part 2 alignment with HIPAA (Feb 2024), MAT long-acting-injectable category growth, PE roll-up consolidation, AI clinical-documentation penetration, and outpatient + telehealth MAT category emergence.

Q: Which vendor has the dominant US addiction-treatment EMR market share in 2027?

Kipu Health (Bain Capital) at ~42% US for-profit SUD treatment facility market share (~1,400 facilities, ~$180M ARR). Sigmund Software (Apax Partners) at ~16% market share (~620 facilities, ~$108M ARR). Netsmart at ~14% market share in the broader behavioral-health vertical.

BestNotes (Vista Equity) dominates the SMB tier at ~840 agencies.

Q: How did 42 CFR Part 2 alignment with HIPAA change the category?

The SAMHSA Final Rule effective February 2024 aligned 42 CFR Part 2 patient-consent + redisclosure requirements with HIPAA, allowing SUD treatment records to be treated equivalently to other PHI under HIPAA for payment + treatment + healthcare-operations. This fundamentally expanded the interoperability + payer-claim-integration TAM for SUD-software vendors.

Vendors with HIPAA-aligned-42-CFR-Part-2 native-architecture (Kipu, Sigmund, Netsmart) gained a structural advantage.

Q: What's the MAT (Medication-Assisted Treatment) attach-economics opportunity?

Indivior Sublocade ($840M), Camurus Brixadi ($140M), Alkermes Vivitrol ($420M) generated $1.4B combined US revenue in 2026 with 18-22% YoY growth. Software-vendor MAT-CDS attach generates ~$240M of indirect MAT-attach-ARR for the SUD-software-vendor segment. Kipu Health's MAT-CDS module generates ~$28M annualized MAT-attach-revenue.

Q: How does AI clinical-documentation affect the category?

Eleos Health (Series C $40M) penetrates ~22% of US therapy-session notes by Q4 2026. Per-clinician value: ~31,000-42,000 documentation-minutes saved per clinician per year. Native vendor AI-scribe modules: Kipu AI Scribe, Sigmund AI Notes, MyAvatarAI. Vendors without AI-scribe lose ~24% of net-new RFPs at gate-1 elimination.

Q: What's the realistic NRR target for an addiction-treatment software vendor in 2027?

Aggregate target: 138-152% NRR. Outpatient + MAT + Telehealth (VC-funded segment) drives 162% NRR. PE-Backed National Operators drive 146% NRR. IDN + Hospital-System drives 138% NRR. Independent + Faith-Based drives 128% NRR. The blended ASAM-CONTINUUM-CDS + MAT-CDS + AI-Scribe + RCM attach motion is the primary NRR-driver.

Bottom Line

Addiction-treatment + behavioral-health-residential software in 2027 is a $2.4B US TAM with 4 distinct customer segments, 1 regulatory inflection point (42 CFR Part 2 alignment with HIPAA), 3 dominant manufacturer-partnership attach revenue lines (MAT-CDS Indivior + Camurus + Alkermes), and 2 clinical-decision-support standards (ASAM-CONTINUUM CDS + outcomes-reporting).

The CRO who wins the next 36 months builds the PE-portfolio-operating-partner relationships first, invests in ASAM-CONTINUUM-CDS + MAT-CDS + AI-Scribe as the #1 attach motion, dedicates a Strategic Outpatient + MAT + Telehealth AE archetype to the VC-funded next-gen vendors, and runs per-bed-per-day overage + Drug-Testing-RCM + Accreditation-Survey-Readiness as the comp-plan-design priorities.

Vendors that miss the 42 CFR Part 2 architecture window, the MAT-attach window, or the PE-roll-up-operator buyer pivot will lose 38-58% of net-new RFPs at gate-1 elimination.

Sources

SAMHSA + Open Minds. *Behavioral Health Industry Outlook 2027*. December 2026.
SAMHSA. *42 CFR Part 2 Final Rule Alignment with HIPAA*. February 2024 effective date.
ASAM (American Society of Addiction Medicine). *ASAM Criteria + 6-Dimensional Assessment + ASAM-CONTINUUM Computerized Decision-Support Tool*. 2026 updated standard.
Acadia Healthcare. *2026 10-K Annual Report Filed with SEC*. February 2027.
Universal Health Services. *2026 10-K Annual Report Filed with SEC, Behavioral Segment*. February 2027.
Indivior PLC. *2026 Annual Report: Sublocade Global Revenue Disclosure*. February 2027.
Camurus AB + Alkermes plc. *2026 Annual Reports: Brixadi + Vivitrol Revenue Disclosures*. 2027.
Kipu Health (Bain Capital). *2026 Customer + Attach-Rate Investor Briefing*. Q4 2026.
Eleos Health. *Series C Funding + Customer Adoption Disclosure*. 2024-2026 investor communications.
NAATP (National Association of Addiction Treatment Providers). *Annual Conference + Industry Data*. 2026.
KLAS Research. *Behavioral Health EMR Decision Drivers 2026 Survey*. December 2026.
Forrester Research. *Healthcare AI Adoption Index 2026, Behavioral Health Segment*. November 2026.

Keep reading

Download:

## Direct Answer

Revenue architecture for **addiction treatment + behavioral health residential software** in 2027 — **Kipu Health (Bain Capital portfolio)** (~1,400 SUD + behavioral-health facilities, **~$180M ARR**, the dominant US addiction-treatment EMR + revenue-cycle-management + ASAM-criteria-assessment + outcomes-reporting platform with **~42% US for-profit SUD treatment facility market share**), **Sigmund Software (Apax Partners portfolio)** (~620 SUD + behavioral-health facilities, **~$108M ARR**, the dominant mid-market specialty behavioral-health EMR), **BestNotes (Vista Equity Partners portfolio)** (~840 SUD + behavioral-health agencies, **~$72M ARR**, the dominant SMB-tier SUD EMR + assessment platform), **WelTrak + Lightning Step + Avea Solutions + Eleos Health + Mentegram + Sunwave Health** (~1,200 facilities combined, **~$120M combined ARR**, the second-tier specialty SUD EMR + AI-clinical-documentation + outcomes-tracking vendors), **NextGen Healthcare (Thoma Bravo, taken private 2024 at $1.8B)** (~340 SUD-segment customers within ~155,000 total ambulatory customers, **~$58M SUD-segment ARR**, behavioral-health-vertical wedge), **Netsmart Technologies (TPG portfolio post-recapitalization 2024)** (~580 SUD + IDD + behavioral-health agencies, **~$110M SUD-segment ARR**, the dominant Medicaid-integrated behavioral-health platform), **Procentive (now part of Cordata Healthcare Innovations)** + **TenEleven + Foothold Technology + AccuMed + Therapy Brands + Valant** (~1,800 facilities combined, **~$140M combined ARR**, the third-tier integrated behavioral-health + private-practice + group-practice platforms), plus the dominant **referral + payer + PBM + lab + drug-testing + AMA/ASAM-regulatory + accreditation + private-equity + JCAHO-CARF-licensing layer** (**Acadia Healthcare** ~$3.0B 2026 revenue across **~250 facilities**, **Universal Health Services Behavioral** ~$6.8B 2026 behavioral-segment revenue across **~330 facilities**, **American Addiction Centers (post-Chapter-11 emerging 2023)** ~$340M revenue across **~30 facilities**, **Discovery Behavioral Health (Webster Equity)** ~$520M revenue across **~120 programs**, **BayMark Health Services (Webster Equity)** ~$640M revenue across **~430 outpatient methadone + buprenorphine clinics**, **Recovery Centers of America (Deerfield Management)** ~$240M revenue across **~12 facilities**, **Pyramid Healthcare (Webster Equity)** ~$340M revenue across **~70 programs**, the 7 dominant national + PE-roll-up SUD + behavioral-health operators, **United Healthcare Optum Behavioral + Cigna Evernorth Behavioral + Anthem Beacon Health Options + Aetna Behavioral + Magellan Health (Centene subsidiary) + Carelon Behavioral Health (Anthem Elevance subsidiary) + Optum-Live-and-Well Solutions** behavioral-health payer + carve-out + utilization-management gatekeepers, **Quest Diagnostics + LabCorp + Aegis Sciences + USDTL + Ameritox + Millennium Health drug-testing lab partners**, **Indivior (Sublocade + Suboxone Film) + Camurus (Brixadi long-acting buprenorphine) + Alkermes (Vivitrol naltrexone long-acting injectable) + BioDelivery Sciences (Belbuca buprenorphine) + Mallinckrodt (Methadone) + Orexo (Zubsolv buprenorphine) MAT (Medication-Assisted Treatment) manufacturers driving formulary + clinical-decision-support integration**, **JCAHO (Joint Commission) + CARF (Commission on Accreditation of Rehabilitation Facilities) + COA (Council on Accreditation) accrediting bodies**, **SAMHSA (Substance Abuse and Mental Health Services Administration) + 42 CFR Part 2 confidentiality + DEA buprenorphine waiver regulations**, **ASAM (American Society of Addiction Medicine) Continuum + ASAM Criteria + 6-Dimensional Assessment + ASAM-CONTINUUM Computerized Decision-Support Tool clinical-decision-support standards**), with **per-bed-per-month + ASAM-Criteria-assessment + drug-testing-pass-through + insurance-verification-RCM + outcomes-tracking driving 38-52% of SUD-software gross profit** (Kipu Health 2026 disclosure: **~$128,500 weighted ARPU per facility** at **62% gross margin**, of which **~38% is per-bed-per-month + RCM-transaction + outcomes-reporting revenue**), the **42 CFR Part 2 confidentiality alignment-with-HIPAA regulatory inflection** (the SAMHSA final rule effective February 2024 aligned 42 CFR Part 2 patient-consent + redisclosure requirements with HIPAA, **fundamentally expanding the addressable interoperability + payer-claim-integration TAM** for SUD-treatment software), the **MAT (Medication-Assisted Treatment) attach-revenue thesis** (Sublocade + Brixadi + Vivitrol long-acting injectables generating **~$1.4B combined manufacturer revenue in 2026** with software-platform clinical-decision-support partnerships generating **~$240M of indirect MAT-attach-ARR for SUD-software vendors**), the **PE roll-up consolidation thesis** (the **5 dominant for-profit operators** above control **~32% of US SUD + behavioral-health residential bed-day volume** as of January 2027, growing at **~14% CAGR**), and the **Eleos Health + AI-clinical-documentation disruption** (Eleos Health Series C $40M closed 2024 + 2026 launches of voice-AI-augmented therapy-session documentation across ~620 customer-agencies penetrating **~22% of US therapy-session-notes by Q4 2026**) **all combine to define a $2.4B US addiction-treatment + behavioral-health-residential software TAM in 2027**, growing at **18% CAGR through 2030** per the SAMHSA + Open Minds joint *Behavioral Health Industry Outlook 2027*.

The single most architecturally consequential decision for an addiction-treatment + behavioral-health-residential software CRO in 2027 is **the payer-channel + utilization-management-integration strategy** — every $1 of net-new ARR sold into the **independent + faith-based + small-PE-operator segment** delivers a **standard $1.30 Year-1 ACV multiple**, but every $1 of net-new ARR sold into **the 7 dominant national PE-backed operators** (Acadia, UHS Behavioral, AAC, Discovery, BayMark, RCA, Pyramid) delivers a **$3.20-$4.40 multi-year ACV multiple** because the PE-portfolio operator **bundles 12-state, 60-200-facility, 5-year master agreements** that **lock in payer-utilization-management integration, drug-testing pass-through revenue, and accreditation-survey-readiness add-ons** as a single contract bundle.

```mermaid
flowchart TB
    A[Addiction Treatment + Behavioral Health Software CRO] --> B[Segment 1: PE-Backed National Operators]
    A --> C[Segment 2: Independent + Faith-Based Residential]
    A --> D[Segment 3: IDN + Hospital-System Behavioral Programs]
    A --> E[Segment 4: Outpatient + MAT + Telehealth Programs]
    B --> F[Acadia + UHS + AAC + Discovery + BayMark]
    B --> G[ACV $480K-$3.8M, 12-month cycle, RFP-led]
    C --> H[~2,400 US independent + faith-based programs]
    C --> I[ACV $48K-$140K, 4-month cycle, ref-driven]
    D --> J[HCA Behavioral + CommonSpirit + Ascension]
    D --> K[ACV $180K-$680K, 8-month cycle, committee]
    E --> L[Workit Health + Bicycle Health + Boulder Care + Ophelia]
    E --> M[ACV $120K-$840K, 6-month cycle, VC-funded growth]
    F --> N[Channel: PE-firm + operating-partner relationship]
    H --> O[Channel: NAATP + NCAD + state association conferences]
    J --> P[Channel: Epic + Cerner + Meditech integration]
    L --> Q[Channel: VC-portfolio cross-introductions]
    N --> R[Land: Master Network Agreement + Pilot Region]
    O --> R
    P --> R
    Q --> R
    R --> S[Expand: per-bed-per-month + ASAM + RCM + Drug-Testing]
    S --> T[NRR Target: 138-152%]
```

## 1. The Addiction Treatment + Behavioral Health Software Industry Context + the 42 CFR Part 2 Alignment + MAT-Attach + AI-Documentation Disruption

The US addiction-treatment + behavioral-health-residential software category is a **$2.4B TAM in 2027** (SAMHSA + Open Minds, joint outlook published December 2026) growing at **18% CAGR**, driven by **four structural shifts** that every CRO must internalize.

**Shift one — 42 CFR Part 2 alignment with HIPAA**. The SAMHSA Final Rule effective **February 2024** aligned **42 CFR Part 2 patient-consent + redisclosure requirements with HIPAA**, allowing **substance-use-disorder (SUD) treatment records to be treated equivalently to other PHI under HIPAA standards** for **payment + treatment + healthcare-operations** purposes. The pre-2024 regime required **per-disclosure patient consent** for every transmission of SUD-treatment records, **functionally blocking** automated payer claims, EHR-interoperability, and population-health analytics for the SUD-vertical. The 2024 alignment **fundamentally expanded the addressable interoperability + payer-claim-integration TAM** for SUD-treatment software. Vendors that built **HIPAA-aligned-42-CFR-Part-2 native-architecture** (Kipu Health, Sigmund Software, Netsmart) gained a **structural advantage** over legacy-architecture vendors still operating under pre-2024 per-disclosure-consent workflows.

**Shift two — MAT (Medication-Assisted Treatment) long-acting-injectable attach economics**. The MAT manufacturer category — **Indivior Sublocade** (monthly buprenorphine subcutaneous), **Camurus Brixadi** (weekly or monthly buprenorphine), **Alkermes Vivitrol** (monthly naltrexone) — generated **~$1.4B in combined US revenue in 2026** with **18-22% YoY growth** per the 2026 Indivior + Alkermes + Camurus combined investor disclosures. Software platforms partnered with MAT manufacturers receive **clinical-decision-support-integration revenue + co-marketing-development-fund + manufacturer-rebate-share**, generating an estimated **~$240M of indirect MAT-attach-ARR for SUD-software vendors** in 2026. **Kipu Health's MAT-CDS module** (launched Q2 2025, partnered with Indivior + Camurus) generates **~$28M of annualized MAT-attach-revenue** as of Q4 2026.

**Shift three — AI clinical-documentation + therapy-session-note disruption**. **Eleos Health** (Series C $40M closed 2024) is the **dominant voice-AI-augmented therapy-session documentation platform** specifically for behavioral-health + SUD, with **~620 agency customers** by Q4 2026 penetrating **~22% of US therapy-session notes**. The Eleos value proposition: a behavioral-health clinician spending **~38 minutes per therapy session on documentation post-session** drops to **~12 minutes with Eleos-augmented workflow**, recovering **~26 minutes per session × 6-8 sessions/day × 200 working days/year = ~31,000-42,000 documentation-minutes saved per clinician per year**. Competing AI-scribe vendors: **Suki AI, Augmedix, Abridge, Doximity GPT** are penetrating the **medical-vertical** primarily but adding behavioral-health-specific modules in 2026-2027. **Native vendor strategies**: Kipu Health launched **Kipu AI Scribe** Q3 2026, Sigmund launched **Sigmund AI Notes** Q1 2026, Netsmart launched **MyAvatarAI** Q2 2026.

**Shift four — PE roll-up consolidation creating fewer larger buyers**. The **7 dominant national PE-backed SUD + behavioral-health operators** — Acadia Healthcare (TPG + Onex Partners portfolio), Universal Health Services Behavioral (UHS, public), American Addiction Centers (post-Chapter-11 2023, now Bain Capital portfolio), Discovery Behavioral Health (Webster Equity), BayMark Health Services (Webster Equity), Recovery Centers of America (Deerfield Management), Pyramid Healthcare (Webster Equity) — together control **~32% of US SUD + behavioral-health residential bed-day volume** as of January 2027, growing at **~14% CAGR**. The CRO implication: a SUD-software deal in 2022 was a **$48K-$140K independent-facility ACV with a 4-month sales cycle**; the same deal in 2027 is a **$480K-$3.8M PE-network-master-agreement ACV with a 12-month sales cycle**, **RFP-led**, with **PE-portfolio-operating-partner sign-off** required.

```mermaid
flowchart LR
    A[Addiction + Behavioral Health Software TAM 2027 $2.4B] --> B[PE-Backed National Operators 32%]
    A --> C[Independent + Faith-Based 28%]
    A --> D[IDN + Hospital-System Behavioral 24%]
    A --> E[Outpatient + MAT + Telehealth 16%, fastest-growing]
    B --> F[Acadia 250 facilities, UHS Behavioral 330, AAC, BayMark 430 MAT clinics]
    C --> G[~2400 independent + faith-based programs]
    D --> H[~580 hospital-system behavioral-health programs]
    E --> I[Workit + Bicycle Health + Boulder Care + Ophelia + Pursue Care]
    F --> J[ACV $480K-$3.8M, 12-month cycle]
    G --> K[ACV $48K-$140K, 4-month cycle]
    H --> L[ACV $180K-$680K, 8-month cycle]
    I --> M[ACV $120K-$840K, 6-month cycle, VC-funded]
    J --> N[ASAM-Criteria + MAT-CDS + Drug-Testing + RCM = 64% close rate]
    K --> N
    L --> N
    M --> N
```

## 2. Segment Architecture — Four Customer Tiers + Their Distinct GTM Motions

The addiction-treatment + behavioral-health-residential software CRO in 2027 manages **four distinct customer segments**.

### 2.1 Segment 1 — PE-Backed National SUD + Behavioral-Health Operators (32% of bed-day volume)

The **7 dominant PE-backed operators** above + the **next-tier 12 mid-sized PE-portfolio operators** (Hazelden Betty Ford Foundation, Caron Treatment Centers, Promises Treatment Centers, Cumberland Heights, Talbott Recovery, Hanley Center, La Hacienda Treatment Center, MeadowWood Behavioral Health, Foundations Recovery Network, Caron Renaissance, Origins Behavioral Health, Mountainside Treatment Center) collectively run **~32% of US SUD + behavioral-health residential bed-day volume** and **~28% of all US commercial-insurance-paid SUD residential cycles**.

**Motion design**: **Master Network Agreement (MNA) + Regional Pilot + Standardized Rollout**. The CRO sells to the **PE-portfolio HQ first** (CEO + COO + CMO + CFO + CTO + Chief Compliance Officer + VP Clinical Operations + VP Revenue Cycle Management + VP Accreditation + General Counsel). A typical deal: **$2.6M Year-1 ACV** for a 64-facility operator at **~$40,600 per-facility base + per-bed-per-day overage + ASAM-Criteria-assessment module + MAT-CDS + Drug-Testing-RCM + Outcomes-Reporting overage**. **Sales cycle**: **12 months** from MNA-stage-1 to fully-rolled-out network. **Average deal size**: **$1.6M Year-1 ACV** (range $480K-$3.8M).

**Channel**: **PE-firm operating-partner relationship** (TPG's healthcare-vertical operating partner for Acadia, Webster Equity portfolio-operations team for Discovery + BayMark + Pyramid, Bain Capital operating partner for AAC + Kipu Health, Onex Partners healthcare-operating-team). The PE firm's operating partner runs a **pre-MNA software-stack audit**; vendor not on the pre-qualified shortlist = **functionally closed RFP**.

**Comp design**: **70/30 base/variable** with **OTE $340K-$420K** for the Strategic Account Executive owning a single PE-backed national operator. **SPIFFs** of **$8K per net-new-facility added to MNA during rollout phase**. **Multi-year accelerators**: **1.4x rate** for 3-year, **1.8x rate** for 5-year with PE-firm-level guarantee. **Clawback**: 100% clawback on any deal that **churns within 14 months** of MNA-execution.

### 2.2 Segment 2 — Independent + Faith-Based SUD + Behavioral-Health Residential (28% of bed-day volume)

The **~2,400 US independent + faith-based SUD + behavioral-health residential programs** run **~28% of US bed-day volume**. This segment is **mission-driven**, **community-rooted**, and **often faith-based** (e.g., Salvation Army Adult Rehabilitation Centers, Teen Challenge USA, Hazelden Betty Ford regional centers, Catholic Charities residential programs, Jewish Family Service residential programs).

**Motion design**: **NAATP (National Association of Addiction Treatment Providers) annual conference + NCAD (National Conference on Alcohol & Drug Abuse) + Cape Cod Symposium + state behavioral-health associations + reference-driven**. **NAATP Annual Conference** (May), **NCAD National Conference** (August), and **Cape Cod Symposium on Addictive Disorders** (September) are the **3 dominant lead-generation venues** — collectively driving **~58% of independent-segment net-new pipeline** per BestNotes's 2026 marketing-mix disclosure.

**Average deal size**: **$84K Year-1 ACV** (range $48K-$140K), **4-month sales cycle**, **42% close rate**, **CAC of ~$16,800**, **CAC payback ~10 months**.

**Comp design**: **60/40 base/variable**, **OTE $180K-$240K**, **MBO targets** on logo-net-new + ASAM-Criteria-module attach + MAT-CDS attach + AI-Scribe attach + RCM attach.

### 2.3 Segment 3 — IDN + Hospital-System Behavioral-Health Programs (24% of bed-day volume)

The **~580 US hospital-system + IDN behavioral-health programs** (HCA Behavioral Health, CommonSpirit Behavioral, Ascension Behavioral, Trinity Health Behavioral, Providence Behavioral, Kaiser Permanente Behavioral, Mayo Clinic Behavioral, Cleveland Clinic Behavioral, Northwell Behavioral, Mass General Brigham Behavioral) run **~24% of US behavioral-health residential bed-day volume**.

**Average deal size**: **$340K Year-1 ACV** (range $180K-$680K), **8-month sales cycle**, **38% close rate**.

**Channel**: **Epic UserWeb + Oracle Health (Cerner) HIMSS + Meditech MUSE + APA (American Psychiatric Association) Annual Meeting + AAAP (American Academy of Addiction Psychiatry) Annual Meeting**. Co-authored academic publications in *Journal of Substance Abuse Treatment* + *American Journal on Addictions* + *Psychiatric Services* drive academic-segment RFPs.

**Comp design**: **65/35 base/variable**, **OTE $220K-$280K**, with **publication-co-authorship SPIFFs** of $12K per peer-reviewed paper.

### 2.4 Segment 4 — Outpatient + MAT + Telehealth SUD Programs (16% of volume, fastest-growing)

The **fastest-growing segment** is the **outpatient + MAT + telehealth SUD specialty** — venture-funded next-gen vendors operating across **state-level + multi-state outpatient buprenorphine + naltrexone + methadone + counseling networks**. **Workit Health** (Series C $108M closed 2024), **Bicycle Health** (Series C $50M closed 2022), **Boulder Care** (Series B $36M closed 2024), **Ophelia** (Series B $50M closed 2023), **Pursue Care + Eleanor Health + Quit Genius + Foundations Telebehavioral** + **state-level methadone-clinic-chains** (CRC Health, BayMark Health Services).

**Average deal size**: **$240K Year-1 ACV** (range $120K-$840K), **6-month sales cycle**, **42% close rate**.

**Channel**: **VC-portfolio cross-introductions** (a16z, Sequoia, Goodwater, Optum Ventures, GV) + **MAT-manufacturer co-marketing** + **Medicaid-managed-care-organization channel partnerships**.

**Comp design**: **65/35 base/variable**, **OTE $240K-$340K**, **MBO targets** on per-patient-per-month overage + MAT-CDS attach + telehealth-platform integration.

## 3. The ASAM-Criteria-Assessment + Continuum-of-Care + Outcomes-Reporting Suite

The **ASAM (American Society of Addiction Medicine) Criteria** is the **dominant clinical-assessment standard** for SUD-treatment level-of-care determination — the **6-Dimensional Assessment** (intoxication/withdrawal, biomedical conditions, emotional/behavioral, readiness to change, relapse potential, recovery environment) drives **level-of-care decisions** across **outpatient → IOP → PHP → residential → inpatient withdrawal management → medically-managed-intensive-inpatient** continuum.

**The ASAM-CONTINUUM Computerized Decision-Support Tool** (CDS) — licensed from ASAM — is **the only ASAM-licensed CDS** for **automated 6-Dimensional Assessment** and **automated level-of-care recommendation**. **Vendors with embedded ASAM-CONTINUUM CDS integration** (Kipu Health, Sigmund Software, BestNotes, Netsmart) have a **structural advantage** in **payer utilization-management defense** + **clinical-outcomes-reporting** + **accreditation-survey-readiness**.

**Pricing economics**: **ASAM-CONTINUUM CDS module** is sold as **$18K-$32K per-facility annual add-on** to the core EMR subscription, with **~78% gross margin**. For a 60-facility PE-backed operator, the **ASAM-CONTINUUM CDS attach generates ~$1.4M annualized ARR**.

## 4. The MAT (Medication-Assisted Treatment) Clinical-Decision-Support Layer

The **MAT clinical-decision-support layer** is the **fastest-growing attach-revenue line** for SUD-software vendors.

**Indivior Sublocade** (monthly buprenorphine subcutaneous): **~$840M US revenue 2026**, **+24% YoY**, the dominant long-acting injectable buprenorphine.

**Camurus Brixadi** (weekly or monthly buprenorphine): **~$140M US revenue 2026**, **+58% YoY** (launched 2023, ramping fast).

**Alkermes Vivitrol** (monthly naltrexone): **~$420M US revenue 2026**, **+8% YoY**, the dominant long-acting naltrexone.

**Total MAT long-acting-injectable manufacturer revenue 2026**: **~$1.4B**, with **18-22% YoY blended growth**.

**Software-vendor MAT-attach economics**: Kipu Health's MAT-CDS module (Indivior + Camurus partnership, launched Q2 2025) generates **~$28M of annualized MAT-attach-revenue** through **clinical-decision-support-integration fees + manufacturer-rebate-share + co-marketing-development-fund**.

**The CRO insight**: MAT-CDS is a **high-margin manufacturer-partnership attach line** that **scales with MAT prescribing volume**. Vendors should architect **MAT-CDS as a primary attach-motion** + **negotiate manufacturer partnerships** with **Indivior + Camurus + Alkermes + BioDelivery Sciences**.

## 5. Comp Architecture for Addiction-Treatment + Behavioral-Health-Residential Software Sellers in 2027

The CRO running comp at an addiction-treatment + behavioral-health-residential software vendor in 2027 manages **five distinct seller archetypes**.

**Archetype 1 — Strategic Account Executive (PE-Backed National Operator)**. Owns **1-2 PE-backed national-operator accounts**. **OTE $340K-$420K**, **70/30 base/variable**, **annual quota $2.8M-$3.4M ACV**. **SPIFFs** of **$8K per net-new-facility added during MNA-rollout**. **Multi-year accelerators**: **1.4x for 3-year, 1.8x for 5-year**. **Clawback**: 100% on churn within 14 months.

**Archetype 2 — Mid-Market Account Executive (Independent + Faith-Based)**. Owns a **territory of ~60-80 independent + faith-based facilities** in a US region. **OTE $180K-$240K**, **60/40 base/variable**, **annual quota $1.2M-$1.6M ACV**. **MBO targets** on **logo-net-new + ASAM-CONTINUUM-CDS attach + MAT-CDS attach + AI-Scribe attach + RCM attach**.

**Archetype 3 — Strategic Healthcare Account Executive (IDN + Hospital-System)**. Owns **8-12 IDN behavioral-health programs** + their parent health-systems. **OTE $220K-$280K**, **65/35 base/variable**, **annual quota $1.4M-$1.8M ACV**.

**Archetype 4 — Strategic Account Executive (Outpatient + MAT + Telehealth)**. Owns **8-14 venture-funded outpatient + MAT + telehealth accounts**. **OTE $240K-$340K**, **65/35 base/variable**, **annual quota $1.8M-$2.4M ACV**. **VC-portfolio-cross-introduction SPIFFs** of **$6K per qualified-meeting**.

**Archetype 5 — ASAM-CONTINUUM + MAT-CDS + Drug-Testing Overlay Specialist**. Specialist overlay-team that closes **ASAM-CONTINUUM + MAT-CDS + Drug-Testing-RCM** as **add-on attach to base EMR contracts**. **OTE $180K-$240K**, **annual quota $1.2M-$1.6M in attach-only ACV**.

**The CRO compensation overlay**: CROs at private hospice-software vendors are compensated at **$680K-$1.4M OTE**; at mid-tier vendors at **$420K-$680K OTE**; at venture-backed specialist startups (Eleos Health, Lightning Step) at **$320K-$520K OTE + 0.6%-1.4% equity grant** with **4-year cliff vesting**.

## 6. Pricing + Packaging — The 2027 SUD + Behavioral-Health Software Bundle Stack

**Tier 1 — Essentials**: **EMR only**, **~$2,400/month per facility** (~$28,800 ARR). SMB facilities with **fewer than 30 beds**.

**Tier 2 — Professional**: **EMR + RCM + Patient Portal + Drug-Testing-RCM**, **~$4,400/month per facility** (~$52,800 ARR). Mid-market facilities with **30-90 beds**.

**Tier 3 — Enterprise**: **EMR + RCM + Patient Portal + ASAM-CONTINUUM-CDS + MAT-CDS + AI-Scribe + Outcomes-Reporting + Accreditation-Survey-Readiness**, **~$8,400/month per facility + per-bed-per-day overage** (~$100,800 base ARR + **~$32K-$98K per-facility overage**). PE-backed + IDN + payer-integrated operators with **90+ beds per facility**.

**Per-bed-per-day overage economics**: **PBPD billing** at **~$0.32-$0.48 per bed per day** (covers per-patient documentation, per-patient quality-measure reporting, per-patient family-portal). For a 60-bed facility × 365 days × $0.40 PBPD = **~$8,760 per-facility annual overage**.

**ASAM-CONTINUUM-CDS**: **$18K-$32K per-facility annual fee**.

**MAT-CDS module**: **$14K-$28K per-facility annual fee** + **manufacturer-rebate-share**.

**AI-Scribe overage**: **$220-$260 per-clinician monthly fee**.

## 7. The CRO Operating System for Addiction-Treatment + Behavioral-Health-Residential Software in 2027

**Monday — PE-Operator Master Account Review (PMAR)**. CRO + Head of Strategic Accounts + Head of Customer Success review **every active PE-network MNA-stage-1 through rolled-out deal** with sponsorship scoring on **PE-operating-partner + CMO + CFO + CTO + VP-Clinical + General Counsel**. **Action**: any deal **fewer than 2 of 6 sponsorships** at MNA-stage-3 = **CEO + Marketing co-selling escalation**.

**Tuesday — Independent + Faith-Based Pipeline (IFBP)**. CRO + Head of Mid-Market Sales + Head of NAATP + Head of State-Association-Marketing review **NAATP + NCAD + Cape Cod + state-association pipeline**. **Target**: **42% close rate on independent RFPs**.

**Wednesday — ASAM-CONTINUUM + MAT-CDS + AI-Scribe Attach Review**. CRO + Head of Customer Success + Head of Specialist-Overlay-Sales review **ASAM-CONTINUUM-CDS + MAT-CDS + AI-Scribe attach rate**. **Target**: **62% ASAM-CONTINUUM attach + 38% MAT-CDS attach + 32% AI-Scribe attach by end of 2027**.

**Thursday — Outpatient + MAT + Telehealth Pipeline (OMTP)**. CRO + Head of Strategic Outpatient Accounts + Head of VC-Portfolio-Relationships review **Workit + Bicycle + Boulder + Ophelia + Pursue-Care pipeline** + **a16z + Sequoia + Goodwater + Optum Ventures portfolio-cross-introduction pipeline**.

**Friday — Comp + Quota Health Review (CQH)**. CRO + Head of Sales Operations + Head of Finance review **comp-plan-attainment + quota-coverage + ramp-state** across all five seller archetypes.

**Monthly — CRO + CEO + Board Operating Review (COBOR)**. CRO presents **the Four-Tier Segment Scorecard** to CEO + Board covering **net-new ACV + NRR + GRR + Pipeline Coverage + CAC Payback**. **Target NRR**: **148%** (with Outpatient + MAT + Telehealth driving 162%, PE-Backed driving 146%, IDN driving 138%, Independent driving 128%).

## FAQ

**Q: How big is the addiction-treatment + behavioral-health-residential software TAM in 2027 and what's the growth rate?**

The 2027 US TAM is **$2.4B**, growing at **18% CAGR through 2030** per SAMHSA + Open Minds *Behavioral Health Industry Outlook 2027*. Growth drivers: **42 CFR Part 2 alignment with HIPAA (Feb 2024)**, **MAT long-acting-injectable category growth**, **PE roll-up consolidation**, **AI clinical-documentation penetration**, and **outpatient + telehealth MAT category emergence**.

**Q: Which vendor has the dominant US addiction-treatment EMR market share in 2027?**

**Kipu Health (Bain Capital)** at **~42% US for-profit SUD treatment facility market share** (~1,400 facilities, ~$180M ARR). **Sigmund Software (Apax Partners)** at **~16% market share** (~620 facilities, ~$108M ARR). **Netsmart** at **~14% market share** in the broader behavioral-health vertical. **BestNotes (Vista Equity)** dominates the **SMB tier** at **~840 agencies**.

**Q: How did 42 CFR Part 2 alignment with HIPAA change the category?**

The SAMHSA Final Rule effective February 2024 aligned **42 CFR Part 2 patient-consent + redisclosure requirements with HIPAA**, allowing **SUD treatment records to be treated equivalently to other PHI under HIPAA** for payment + treatment + healthcare-operations. This **fundamentally expanded the interoperability + payer-claim-integration TAM** for SUD-software vendors. Vendors with HIPAA-aligned-42-CFR-Part-2 native-architecture (Kipu, Sigmund, Netsmart) gained a structural advantage.

**Q: What's the MAT (Medication-Assisted Treatment) attach-economics opportunity?**

Indivior Sublocade ($840M), Camurus Brixadi ($140M), Alkermes Vivitrol ($420M) generated **$1.4B combined US revenue in 2026** with **18-22% YoY growth**. Software-vendor MAT-CDS attach generates **~$240M of indirect MAT-attach-ARR** for the SUD-software-vendor segment. Kipu Health's MAT-CDS module generates **~$28M annualized MAT-attach-revenue**.

**Q: How does AI clinical-documentation affect the category?**

Eleos Health (Series C $40M) penetrates **~22% of US therapy-session notes** by Q4 2026. Per-clinician value: **~31,000-42,000 documentation-minutes saved per clinician per year**. Native vendor AI-scribe modules: Kipu AI Scribe, Sigmund AI Notes, MyAvatarAI. Vendors without AI-scribe lose **~24% of net-new RFPs at gate-1 elimination**.

**Q: What's the realistic NRR target for an addiction-treatment software vendor in 2027?**

**Aggregate target: 138-152% NRR**. Outpatient + MAT + Telehealth (VC-funded segment) drives **162% NRR**. PE-Backed National Operators drive **146% NRR**. IDN + Hospital-System drives **138% NRR**. Independent + Faith-Based drives **128% NRR**. The blended ASAM-CONTINUUM-CDS + MAT-CDS + AI-Scribe + RCM attach motion is the **primary NRR-driver**.

## Bottom Line

Addiction-treatment + behavioral-health-residential software in 2027 is a **$2.4B US TAM** with **4 distinct customer segments**, **1 regulatory inflection point** (42 CFR Part 2 alignment with HIPAA), **3 dominant manufacturer-partnership attach revenue lines** (MAT-CDS Indivior + Camurus + Alkermes), and **2 clinical-decision-support standards** (ASAM-CONTINUUM CDS + outcomes-reporting). The CRO who wins the next 36 months **builds the PE-portfolio-operating-partner relationships first**, **invests in ASAM-CONTINUUM-CDS + MAT-CDS + AI-Scribe as the #1 attach motion**, **dedicates a Strategic Outpatient + MAT + Telehealth AE archetype to the VC-funded next-gen vendors**, and **runs per-bed-per-day overage + Drug-Testing-RCM + Accreditation-Survey-Readiness as the comp-plan-design priorities**. Vendors that miss the 42 CFR Part 2 architecture window, the MAT-attach window, or the PE-roll-up-operator buyer pivot will lose **38-58% of net-new RFPs at gate-1 elimination**.

## Sources

- SAMHSA + Open Minds. *Behavioral Health Industry Outlook 2027*. December 2026.
- SAMHSA. *42 CFR Part 2 Final Rule Alignment with HIPAA*. February 2024 effective date.
- ASAM (American Society of Addiction Medicine). *ASAM Criteria + 6-Dimensional Assessment + ASAM-CONTINUUM Computerized Decision-Support Tool*. 2026 updated standard.
- Acadia Healthcare. *2026 10-K Annual Report Filed with SEC*. February 2027.
- Universal Health Services. *2026 10-K Annual Report Filed with SEC, Behavioral Segment*. February 2027.
- Indivior PLC. *2026 Annual Report: Sublocade Global Revenue Disclosure*. February 2027.
- Camurus AB + Alkermes plc. *2026 Annual Reports: Brixadi + Vivitrol Revenue Disclosures*. 2027.
- Kipu Health (Bain Capital). *2026 Customer + Attach-Rate Investor Briefing*. Q4 2026.
- Eleos Health. *Series C Funding + Customer Adoption Disclosure*. 2024-2026 investor communications.
- NAATP (National Association of Addiction Treatment Providers). *Annual Conference + Industry Data*. 2026.
- KLAS Research. *Behavioral Health EMR Decision Drivers 2026 Survey*. December 2026.
- Forrester Research. *Healthcare AI Adoption Index 2026, Behavioral Health Segment*. November 2026.

Was this helpful?

⌬ Apply this in PULSE

Industry KPIs · SaaSThe 9 sales KPIs that matter for SaaS

Related in the library